Results 11 to 20 of about 570,743 (130)

Left main bronchus compression due to main pulmonary artery dilatation in pulmonary hypertension: two case reports [PDF]

open access: yes, 2015
. Pulmonary arterial dilatation associated with pulmonary hypertension may result in significant compression of local structures. Left main coronary artery and left recurrent laryngeal nerve compression have been described.
Ariff, B   +6 more
core   +1 more source

Pulmonary hypertension: evolution of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension [PDF]

open access: yesJournal of Thoracic Disease, 2016
On May 16 th , 2016, Nick H. Kim, MD [University of California San Diego (UCSD), Division of Pulmonary, Critical Care & Sleep Medicine] delivered his keynote presentation outlining the current state of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
Anderson, Ryan J   +2 more
openaire   +5 more sources

Non-invasive assessment of pulmonary vascular resistance in pulmonary hypertension: Current knowledge and future direction [PDF]

open access: yes, 2017
Pulmonary Hypertension (PHT) is relatively common, dangerous and under-recognised. Pulmonary hypertension is not a diagnosis in itself; it is caused by a number of differing diseases each with different treatments and prognoses.
Hills, G   +4 more
core   +2 more sources

ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs. [PDF]

open access: yes, 2020
Pulmonary hypertension (PH), defined by increased pressure within the pulmonary vasculature, is a hemodynamic and pathophysiologic state present in a wide variety of cardiovascular, respiratory, and systemic diseases.
Abbott, Jonathan   +9 more
core   +3 more sources

Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor [PDF]

open access: yes, 2002
BACKGROUND: Mutations in the type II receptor for bone morphogenetic protein (BMPR-II), a receptor member of the transforming growth factor-beta (TGF-beta) superfamily, underlie many familial and sporadic cases of primary pulmonary hypertension (PPH ...
Atkinson, Carl   +6 more
core   +1 more source

MicroRNA410 Inhibits Pulmonary Vascular Remodeling via Regulation of Nicotinamide Phosphoribosyltransferase [PDF]

open access: yes, 2019
Nicotinamide phosphoribosyltransferase (NAMPT) upregulation in human pulmonary artery endothelial cells (hPAECs) is associated with pulmonary arterial hypertension (PAH) progression and pulmonary vascular remodeling.
Chen, Jiwang   +7 more
core   +1 more source

Micro-RNA-1 is decreased by hypoxia and contributes to the development of pulmonary vascular remodeling via regulation of sphingosine kinase 1 [PDF]

open access: yes, 2018
Sphingosine kinase 1 (SphK1) upregulation is associated with pathologic pulmonary vascular remodeling in pulmonary arterial hypertension (PAH), but the mechanisms controlling its expression are undefined.
Chen, Jiwang   +6 more
core   +1 more source

Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension [PDF]

open access: yes, 2018
Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models.
Alastalo   +23 more
core   +4 more sources

Pulmonary hypertension [PDF]

open access: yesCurrent Problems in Cardiology, 2004
Pulmonary hypertension, in its simplest sense, is elevation of the pulmonary artery pressure above normal. A multitude of diseases may increase the pulmonary artery pressure and result in right ventricular dysfunction. The treatments of pulmonary hypertension are as varied as its causes.
Vallerie V, McLaughlin, Stuart, Rich
openaire   +2 more sources

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. [PDF]

open access: yes, 2013
BACKGROUND: Riociguat, a member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension. METHODS: In this phase 3,
CHEST-1 Study Group,   +13 more
core   +1 more source

Home - About - Disclaimer - Privacy